PBYI

Puma Biotechnology, Inc. NASDAQ

Healthcare ·Biotechnology ·US · pumabiotechnology.com

$7.53

Mkt Cap $383.2M

52w Low $2.85 92.7% of range 52w High $7.90

50d MA $6.81 200d MA $5.64

P/E (TTM) 12.1x

EV/EBITDA 5.6x

P/B 2.9x

Debt/Equity 0.2x

ROE 23.9%

P/FCF 7.1x

RSI (14) —

ATR (14) —

Beta 1.18

50d MA $6.81

200d MA $5.64

Avg Volume 369.0K

About

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabin…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	0.24	0.29	+20.8%	7.60	-17.1%	-25.0%	-15.5%	-18.3%	-15.8%	-18.0%	—
Nov 6, 2025	AMC	0.09	0.21	+133.3%	4.90	+8.8%	+22.2%	-3.5%	+5.9%	+1.8%	+1.0%	—
Aug 7, 2025	AMC	0.11	0.15	+36.4%	3.29	-7.3%	+12.2%	+47.4%	+48.0%	+61.1%	+61.7%	—
May 8, 2025	AMC	0.02	0.10	+400.0%	3.07	+1.3%	-5.2%	-1.0%	-2.0%	-5.5%	+6.8%	—
Feb 27, 2025	AMC	0.10	0.43	+330.0%	2.99	+3.3%	+19.7%	+12.0%	+13.4%	+18.4%	+21.1%	—
Nov 7, 2024	AMC	0.35	0.41	+17.1%	3.03	+11.9%	-5.0%	+8.9%	+5.9%	-2.0%	-1.3%	—
Aug 1, 2024	AMC	-0.10	-0.05	+50.0%	3.50	-6.3%	+9.4%	+2.6%	+15.1%	+6.6%	+9.4%	—
May 2, 2024	AMC	-0.16	-0.05	+68.8%	4.96	+2.8%	-2.0%	-6.9%	-4.2%	-2.6%	-3.4%	—
Feb 29, 2024	AMC	0.30	0.26	-13.3%	6.22	-14.0%	-5.3%	-13.8%	-16.7%	-11.1%	-7.6%	—
Nov 2, 2023	AMC	0.08	0.12	+50.0%	2.49	-1.2%	+11.6%	+12.9%	+16.5%	+26.9%	+32.9%	—
Aug 3, 2023	AMC	0.07	0.10	+42.9%	3.52	-4.0%	+8.5%	+11.9%	+16.2%	+15.9%	+14.5%	—
May 4, 2023	AMC	0.04	0.09	+142.7%	2.61	+11.1%	+20.7%	+22.6%	+20.3%	+18.0%	+13.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.99	$3.09	+3.3%	+19.7%	+12.0%	+13.4%	+18.4%	+21.1%
Dec 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.75	$2.77	+0.7%	+2.2%	+9.8%	+14.5%	+12.0%	+13.8%
Nov 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.74	$2.74	+0.0%	+3.6%	+5.8%	+9.5%	+10.2%	+14.6%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.03	$3.39	+11.9%	-5.0%	+8.9%	+5.9%	-2.0%	-1.3%
Aug 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.50	$3.28	-6.3%	+9.4%	+2.6%	+15.1%	+6.6%	+9.4%
Jul 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.94	$3.99	+1.3%	-2.8%	-8.4%	-8.1%	-8.9%	-11.2%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.79	$3.79	+0.0%	-4.7%	-3.4%	-6.1%	-6.9%	-7.9%
Jun 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.85	$3.91	+1.6%	-1.6%	-6.2%	-4.9%	-7.5%	-8.3%
May 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.10	$4.13	+0.7%	+6.6%	+1.7%	+3.2%	-2.7%	-2.4%
May 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.96	$5.10	+2.8%	-2.0%	-6.9%	-4.2%	-2.6%	-3.4%
Mar 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.22	$5.35	-14.0%	-5.3%	-13.8%	-16.7%	-11.1%	-7.6%
Feb 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.36	$6.34	-0.3%	-2.4%	+16.4%	+9.9%	+11.8%	+6.8%
Sep 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.98	$3.04	+2.0%	-2.7%	-2.7%	-3.0%	-7.0%	-8.7%
Aug 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.52	$3.38	-4.0%	+8.5%	+11.9%	+16.2%	+15.9%	+14.5%
Jun 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.55	$3.59	+1.1%	+0.6%	-0.3%	+0.6%	-1.1%	-4.8%
May 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.61	$2.90	+11.1%	+20.7%	+22.6%	+20.3%	+18.0%	+13.8%
Mar 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.21	$3.19	-0.6%	-6.2%	-8.1%	-12.1%	-15.6%	-19.3%
Aug 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.75	$2.80	+1.8%	-2.5%	-4.7%	-6.2%	-10.2%	-9.5%
Aug 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.27	$3.40	+4.0%	+17.4%	+6.7%	+11.6%	+9.2%	+8.6%
May 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.24	$2.39	+6.7%	-11.2%	-25.0%	-18.8%	-26.8%	-21.9%
Sep 28	Citigroup	Upgrade	Neutral → Buy	—	$7.12	$7.64	+7.3%	+2.5%	-1.3%	-1.5%	-9.1%	-11.9%
Aug 6	Goldman Sachs	Maintains	Sell → Sell	—	$6.99	$6.80	-2.7%	+1.6%	-0.4%	+1.6%	+3.1%	+4.1%
Aug 6	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$6.99	$6.80	-2.7%	+1.6%	-0.4%	+1.6%	+3.1%	+4.1%
Aug 10	Citigroup	Maintains	Neutral → Neutral	—	$10.27	$10.12	-1.5%	+2.6%	-2.3%	-3.4%	-3.5%	-4.3%
Aug 7	SVB Leerink	Maintains	Market Perform → Market Perform	—	$10.38	$10.38	+0.0%	-1.1%	+1.5%	-3.4%	-4.4%	-4.5%
Jun 25	BofA Securities	Maintains	Underperform → Underperform	—	$11.39	$10.91	-4.2%	-6.0%	-9.4%	-10.2%	-8.4%	-6.5%
May 20	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$11.84	$12.09	+2.1%	+3.1%	+0.9%	-1.1%	-1.9%	-8.8%
Dec 6	H.C. Wainwright	Maintains	Buy → Buy	—	$7.44	$7.81	+5.0%	+5.9%	+3.4%	+14.1%	+16.8%	+24.9%
Oct 8	Goldman Sachs	Downgrade	Neutral → Sell	—	$10.07	$8.88	-11.8%	-21.9%	-24.0%	-28.0%	-29.2%	-32.7%
Aug 9	Barclays	Maintains	Underweight → Underweight	—	$9.21	$11.13	+20.8%	+21.2%	+20.4%	+20.3%	+9.1%	+2.4%
May 10	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$30.02	$18.70	-37.7%	-38.6%	-43.7%	-41.5%	-44.7%	-43.8%
May 10	Citigroup	Downgrade	Buy → Neutral	—	$30.02	$18.70	-37.7%	-38.6%	-43.7%	-41.5%	-44.7%	-43.8%
May 10	Citi	Downgrade	Buy → Neutral	—	$30.02	$18.70	-37.7%	-38.6%	-43.7%	-41.5%	-44.7%	-43.8%
Mar 1	Citigroup	Maintains	Buy → Buy	—	$27.81	$36.85	+32.5%	+40.0%	+44.1%	+38.9%	+31.8%	+37.3%
Jan 17	Leerink Swann	Maintains	Market Perform → Perform	—	$25.33	$25.11	-0.9%	+0.6%	-0.4%	-6.5%	-3.0%	+3.4%
Jan 3	Guggenheim	Downgrade	Buy → Neutral	—	$21.68	$20.82	-4.0%	-4.2%	-1.4%	+8.5%	+11.9%	+9.5%
Nov 19	Goldman Sachs	Upgrade	Sell → Neutral	—	$23.58	$24.19	+2.6%	-2.1%	-1.9%	-0.1%	-1.4%	-0.0%
Nov 2	Barclays	Downgrade	Equal Weight → Underweight	—	$38.60	$24.00	-37.8%	-48.0%	-40.8%	-42.0%	-40.2%	-39.9%
Nov 2	JP Morgan	Maintains	Underweight → Underweight	—	$38.60	$24.00	-37.8%	-48.0%	-40.8%	-42.0%	-40.2%	-39.9%
Nov 2	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$38.60	$24.00	-37.8%	-48.0%	-40.8%	-42.0%	-40.2%	-39.9%
Oct 1	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$45.85	$46.85	+2.2%	+0.9%	+1.9%	+1.2%	-4.7%	-2.8%
Sep 18	Citigroup	Maintains	Buy → Buy	—	$44.10	$45.20	+2.5%	+6.0%	+8.4%	+7.8%	+7.7%	+7.5%
Sep 17	Goldman Sachs	Maintains	Sell → Sell	—	$47.00	$45.55	-3.1%	-6.2%	-0.5%	+1.7%	+1.2%	+1.1%
Aug 10	JP Morgan	Maintains	Overweight → Overweight	—	$48.65	$54.00	+11.0%	-8.1%	-10.0%	-7.8%	-12.7%	-12.3%
Jun 28	Citigroup	Maintains	Buy → Buy	—	$56.80	$57.40	+1.1%	-0.8%	+4.1%	+4.8%	+1.0%	+3.4%
Apr 12	Barclays	Downgrade	Overweight → Equal Weight	—	$66.15	$62.30	-5.8%	+1.4%	+0.4%	-0.1%	+1.0%	-1.8%
Mar 9	Stifel	Maintains	Buy → Buy	—	$80.85	$82.45	+2.0%	-0.1%	-1.7%	-8.7%	-8.2%	-8.0%
Mar 9	Stifel Nicolaus	Maintains	Buy → Buy	—	$80.85	$82.45	+2.0%	-0.1%	-1.7%	-8.7%	-8.2%	-8.0%
Mar 2	Barclays	Maintains	Overweight → Overweight	—	$61.75	$61.95	+0.3%	+15.1%	+23.6%	+23.5%	+29.1%	+30.9%
Jan 24	BofA Securities	Maintains	Buy → Buy	—	$90.90	$66.95	-26.3%	-28.8%	-25.1%	-24.4%	-24.2%	-27.7%

Recent Filings

8-K

PUMA BIOTECHNOLOGY INC -- 8-K Filing

Puma Biotechnology reported its 2025 financial results, showing fourth-quarter and full-year performance for the biopharmaceutical company, providing investors insight into operational and commercial progress.

Feb 26

Data updated apr 26, 2026 6:53pm · Source: massive.com